Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.12 +3.3%	$4.22	$3.00 ▼ $25.45	$189.97M	0.47	533,249 shs	445,260 shs
CYCC Cyclacel Pharmaceuticals	$2.00 -9.1%	$4.06	$1.95 ▼ $49.34	$28.51M	0.52	104,885 shs	144,475 shs
NAGE Niagen Bioscience	$10.95 +4.3%	$7.59	$2.31 ▼ $10.99	$862.53M	1.94	842,541 shs	1.05 million shs
RCKT Rocket Pharmaceuticals	$6.50 -3.3%	$6.93	$4.55 ▼ $26.98	$694.11M	1.02	1.49 million shs	3.23 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	+3.26%	+2.49%	-11.21%	+11.35%	-80.37%
CYCC Cyclacel Pharmaceuticals	-9.09%	-50.81%	-42.24%	-66.37%	-94.88%
NAGE Niagen Bioscience	+4.29%	+22.35%	+67.43%	+86.54%	+220.18%
RCKT Rocket Pharmaceuticals	-3.27%	-6.74%	+5.69%	-37.92%	-72.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	1.9116 of 5 stars	2.9	0.0	0.0	0.0	2.0	1.7	1.3
CYCC Cyclacel Pharmaceuticals	0.6468 of 5 stars	0.0	2.0	0.0	0.0	2.9	2.5	0.0
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.7839 of 5 stars	4.5	1.0	0.0	4.7	3.1	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	264.08% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
NAGE Niagen Bioscience	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$37.73	480.42% Upside

Current Analyst Ratings Breakdown

Latest CRGX, RCKT, CYCC, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $30.00
5/16/2025	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $32.00
5/16/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
5/12/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $51.00
5/12/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
5/9/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$54.00 ➝ $45.00
5/9/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $44.00
5/9/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
4/9/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/12/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00

(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
CYCC Cyclacel Pharmaceuticals	$43K	602.74	N/A	N/A	$0.57 per share	3.51
NAGE Niagen Bioscience	$107.93M	7.99	N/A	N/A	N/A	∞
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$98.15M	-$4.62	N/A	N/A	N/A	N/A	-38.16%	-33.94%	N/A
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$56.00	N/A	∞	N/A	-18,150.00%	-1,901.11%	-188.23%	N/A
NAGE Niagen Bioscience	N/A	$0.17	64.41	∞	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest CRGX, RCKT, CYCC, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
4/2/2025	Q4 2024	CYCC Cyclacel Pharmaceuticals	-$4.64	-$5.28	-$0.64	-$0.33	$0.01 million	$0.01 million
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	$0.15	7.50%	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRGX, RCKT, CYCC, and NAGE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/28/2025	CYCC Cyclacel Pharmaceuticals		$2.40		4/29/2025	4/29/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	18.94	18.95
CYCC Cyclacel Pharmaceuticals	N/A	0.77	0.77
NAGE Niagen Bioscience	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
CYCC Cyclacel Pharmaceuticals	23.58%
NAGE Niagen Bioscience	15.41%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
CYCC Cyclacel Pharmaceuticals	68.00%
NAGE Niagen Bioscience	9.39%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	46.11 million	45.39 million	N/A
CYCC Cyclacel Pharmaceuticals	14	12.96 million	4.78 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	N/A	N/A
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

CRGX, RCKT, CYCC, and NAGE Headlines

Recent News About These Companies

Prosight Management LP Buys 929,337 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 17 at 7:01 AM | marketbeat.com

MPM Bioimpact LLC Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 16 at 8:38 AM | marketbeat.com

Cantor Fitzgerald Issues Positive Estimate for RCKT Earnings

May 16 at 6:28 AM | marketbeat.com

LMR Partners LLP Takes $943,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 16 at 5:44 AM | marketbeat.com

Janus Henderson Group PLC Acquires 2,106,699 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 16 at 5:22 AM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 7.5% After Analyst Downgrade

May 15 at 11:13 AM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at Scotiabank

May 14 at 12:06 PM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $34.00 Price Target at Canaccord Genuity Group

May 14 at 10:07 AM | marketbeat.com

Scotiabank Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

May 14 at 1:57 AM | americanbankingnews.com

Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

May 14 at 1:57 AM | americanbankingnews.com

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | insidermonkey.com

Algert Global LLC Invests $504,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 13, 2025 | marketbeat.com

Rocket Pharmaceuticals price target lowered to $51 from $52 at Scotiabank

May 12, 2025 | msn.com

Dimensional Fund Advisors LP Has $9.57 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 12, 2025 | marketbeat.com

The Goldman Sachs Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $13.00

May 12, 2025 | americanbankingnews.com

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

May 9, 2025 | businesswire.com

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

May 9, 2025 | zacks.com

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 8, 2025 | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bamco Inc. NY

May 8, 2025 | marketbeat.com

Avidity Partners Management LP Boosts Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 6, 2025 | marketbeat.com

Baker BROS. Advisors LP Buys Shares of 97,079 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRGX, RCKT, CYCC, and NAGE Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.12 +0.13 (+3.26%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$4.09 -0.03 (-0.83%)

As of 05/16/2025 06:49 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$2.00 -0.20 (-9.09%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.04 +0.04 (+2.25%)

As of 05/16/2025 07:30 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Niagen Bioscience NASDAQ:NAGE

$10.95 +0.45 (+4.29%)

As of 05/16/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Rocket Pharmaceuticals NASDAQ:RCKT

$6.50 -0.22 (-3.27%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$6.66 +0.16 (+2.46%)

As of 05/16/2025 07:48 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time